Molly Henderson - Nov 30, 2021 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Chief Financial Officer
Signature
/s/ Jason Smith, Attorney-in-Fact
Stock symbol
URGN
Transactions as of
Nov 30, 2021
Transactions value $
-$31,122
Form type
4
Date filed
12/2/2021, 12:15 PM
Previous filing
Jun 8, 2021
Next filing
Feb 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise +5K +200% 7.5K Nov 30, 2021 Direct F1
transaction URGN Ordinary Shares Sale -$31.1K -2.59K -34.49% $12.03 4.91K Nov 30, 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Restricted Stock Units Options Exercise $0 -5K -33.33% $0.00 10K Nov 30, 2021 Ordinary Shares 5K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer
F2 Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units
F3 1/3 of the shares underlying the stock options will vest on each of November 30, 2021, October 1, 2022 and October 1, 2023.